Change in Pattern of Relapse After Antiangiogenic Therapy in High-Grade Glioma

Along with an increase in median progression-free survival, bevacizumab therapy increased the risk of DIR in HGG patients. The risk of increased invasion with prolonged angiogenic blockade should be addressed in future clinical trials.